BioSpace News Archive

Onxeo S.A. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office, granting the Company a new patent covering the combination of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, with any PARP inhibitor for cancer treatment, in the United States.

Some of the most deadly skin cancers may start in stem cells that lend color to hair, and originate in hair follicles rather than in skin layers, a new study finds.

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $0.53 million for eligible research and development expenditure incurred during the 2019 Financial Year.

Historic gift will establish the Huntsman Mental Health Institute with an initial focus on advancing knowledge and relieving suffering through research-informed treatment of mental illness with a strong focus on improving mental health services for college-age adults, increasing access to mental health services in rural communities across Utah and identifying the genetic underpinnings of mental illness.

The Healthy Kids, Healthy Families® grants support ongoing efforts to raise awareness around two chronic conditions impacting the health of Texans

Low cost, customized printed inserts to reduce spinal curvature, hip replacement and knee replacement for millions of people

Le Bonheur Children’s Hospital has launched an Infantile Epilepsy Center that focuses on the potentially devastating diagnosis of infantile spasms and other rare epilepsies that affect children under two-years-old.

Abuse, neglect and family violence lead the list of ACEs that contribute to poor self-control

Technavio has announced its latest market research report titled global digital dose inhaler market 2019-2023.

The vast majority of ovarian cancers don’t become apparent until they are advanced, making the chance of successful treatment to control these tumors quite slim.